Compare VICR & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VICR | DVA |
|---|---|---|
| Founded | 1981 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 15.1B |
| IPO Year | 1995 | 2003 |
| Metric | VICR | DVA |
|---|---|---|
| Price | $276.03 | $233.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $217.50 | $156.75 |
| AVG Volume (30 Days) | 715.4K | ★ 732.3K |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1764.29 | N/A |
| EPS | 0.44 | ★ 2.87 |
| Revenue | $452,701,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $37.01 | $3.85 |
| Revenue Next Year | $39.47 | $3.07 |
| P/E Ratio | $632.18 | ★ $79.91 |
| Revenue Growth | ★ 26.08 | 6.46 |
| 52 Week Low | $41.76 | $101.00 |
| 52 Week High | $382.65 | $239.64 |
| Indicator | VICR | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 74.75 |
| Support Level | $241.14 | $145.58 |
| Resistance Level | $305.39 | N/A |
| Average True Range (ATR) | 27.82 | 6.30 |
| MACD | -9.74 | 0.51 |
| Stochastic Oscillator | 21.11 | 80.93 |
Vicor Corp manufactures and markets modular power components and complete power systems for converting electrical power. It provides modular power converters and configurable products, power component products and integrated circuits, and related products. Its products include Converters, Power Systems, Filters, Custom Power Systems, Input Modules, and others. The principal markets for the Company's power converters and systems are large original equipment manufacturers (OEMs), original design manufacturers (ODMs) and their contract manufacturers, and smaller, lower volume users, which are broadly distributed across several market areas.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.